top of page

De-risk your drug discovery using genetic evidence

Clinical programs with genetics evidence are 2–3x more likely to succeed*. Variantt makes these insights accessible without a full genetics department.

​

Discover how genetics evidence can de-risk your pipeline

​

*Based on Minikel et al., Nature 2024​​

Our offer

Variantt delivers trusted genetics evidence to help drug discovery teams choose the right targets

Aggregates and integrates multiple high-quality datasources

Provides full data provenance for confidence and reproducibility

Offers causal evidence to validate targets

To hear more and discuss how we could help you,  please get in touch.

Designed for drug discovery scientists - not just bioinformatics experts

In Phase II, most drugs fail.

Early decisions guided by genetic evidence could change that.

  • 7 out of 10 Phase 2 clinical trials fail.

  • 50% of failures are due to efficacy.

  • Many failures begin with the wrong target, a decision made at the very start of discovery.

  • Each phase II failure can cost $50M or more and years of effort.

bottom of page